Telix Pharmaceuticals (ASX: TLX | NASDAQ: TLX) is a commercial-stage radiopharmaceutical company focused on precision diagnostics and therapeutics, primarily in oncology.
- Global footprint across the US, Europe, Australia, Japan and now expanding into China
- Core revenue engine already commercial, not a “hope-and-pray” biotech
- Market cap sits in large-cap ASX healthcare territory, widely held by institutions
This is not a speculative pre-revenue biotech: Telix is now a scaled healthcare business with material cash flow, reinvesting aggressively into a deep pipeline.
Main Products or Services
Commercial Products (Revenue-generating):
- Illuccix® (PSMA-PET imaging)
FDA-approved, dominant in prostate cancer imaging - Gozellix®
Next-generation PSMA-PET agent, US reimbursement live from Oct 2025
These two products are already driving hundreds of millions in annual revenue.
Pipeline (Value Optionality):
- TLX591-Tx (Phase 3 prostate cancer therapy)
- TLX250-Tx (kidney cancer)
- TLX101-Tx (glioblastoma)
- Multiple alpha-emitter programs
This matters because the market is currently valuing TLX mainly as an imaging business, while the therapy pipeline remains largely under-priced.
Fundamental Overview
✅ FY25 Revenue: US$804M (≈ A$1.2B)
✅ YoY Revenue Growth: +59% (FY24 → FY25)
✅ Q4 FY25 Revenue: US$208M, +46% YoY
✅ Guidance hit at the top end, no miss, no excuses
✅ FY24 is the first clean, meaningful profitable year
| Financial Year | Revenue (USD) | Net Profit (USD) | Profitability Status |
|---|---|---|---|
| FY21 | ~$5.7M | –$60.4M | 🚩 Loss-making |
| FY22 | ~$111.0M | –$72.1M | 🚩 Loss-making |
| FY23 | ~$333.5M | +$3.45M | 🚩 Near breakeven |
| FY24 | ~$516.4M | +$32.9M | ✅ Profitable |
Macro Outlook
Demand for PSMA imaging is structurally growing, reimbursement is expanding, and clinical guidelines are moving in Telix’s favour. There are execution risks, but from a macro and industry perspective, the wind is at Telix’s back, not in its face. Telix operates a market-leading PSMA imaging portfolio through Illuccix and Gozellix, already commercialised and reimbursed in the U.S. The current U.S. addressable market for PSMA-PET imaging is estimated at ~US$2.5B+, representing existing clinical demand rather than a theoretical opportunity.
The next phase of growth is driven by market expansion rather than market share gains. Through the BiPASS study (PSMA-PET combined with MRI), Telix aims to move imaging earlier in the prostate cancer diagnostic pathway, potentially reducing unnecessary biopsies and increasing scan volumes. This expands the addressable market to approximately US$3.5B+.
Further upside exists through label expansion, subject to successful registration-enabling studies and regulatory approvals. If achieved, broader indications could increase the PSMA imaging opportunity to ~US$6.7B+, driven by higher utilisation, additional patient cohorts, and expanded clinical guidelines.
From a competitive standpoint, Telix benefits from its AlFluor™ platform, which enables flexible radiolabelling of PSMA-11 using either gallium-68 or alternative isotopes. This provides manufacturing flexibility, supply chain resilience, and a structural advantage over single-product competitors.
Overall, Telix’s PSMA franchise is built on a commercially proven base with clear, execution-driven upside, where a significant portion of long-term market expansion is not yet fully reflected in the current share price.Demand for PSMA imaging is structurally growing, reimbursement is expanding, and clinical guidelines are moving in Telix’s favour. There are execution risks, but from a macro and industry perspective, the wind is at Telix’s back, not in its face.
Innovation | Product & Treatment Pipeline (Telix)
Telix’s innovation stack is layered, cash-generating diagnostics today, execution-driven expansion tomorrow, and asymmetric optionality longer term. Below we have categorised each Product/Program and most importantly the Estimated VAlidation and commercialisation lead time projection.
| Category | Product / Program | Innovation Description | Indication | Current Stage | Monetisation Status | Estimated Validation / Commercial Timeline |
|---|---|---|---|---|---|---|
| Diagnosis (Commercial) | Illuccix® (Ga-68 PSMA-PET) | PSMA-targeted PET imaging replacing conventional CT/bone scans; higher accuracy for prostate cancer staging | Prostate cancer imaging | Fully approved (FDA, TGA, EU, etc.) | Commercial, reimbursed, scaling globally | Already monetising |
| Diagnosis (Commercial) | Gozellix® | Next-generation PSMA-PET agent with longer shelf life, improved production scalability and logistics | Prostate cancer imaging | FDA-approved, US reimbursement live | Commercial, early ramp phase | Already monetising |
| Platform (Commercial) | AlFluor™ Radiolabelling Platform | Flexible isotope labelling (Ga-68 or alternatives) improving supply chain resilience and differentiation | Imaging & therapy enablement | Integrated into commercial products | Indirectly monetised via products | Already monetising |
| Diagnosis (Expansion) | BiPASS (PSMA-PET + MRI) | Uses PSMA-PET + MRI at initial diagnosis to reduce unnecessary biopsies and improve accuracy | Prostate cancer diagnosis | Phase 3 registrational study (dosing patients) | Not yet monetised (label expansion dependent) | 12–24 months (if successful) |
| Therapy (Mid-term) | TLX591-Tx (¹⁷⁷Lu-PSMA) | Theranostic therapy leveraging PSMA imaging to guide targeted treatment | Advanced prostate cancer | Phase 3 (Part 1 data readout imminent) | Not monetised | 18–36 months |
| Therapy (Mid-term) | TLX250-Tx (CAIX-targeted) | First-in-class radiopharmaceutical therapy for kidney cancer | Renal cell carcinoma (ccRCC) | Phase 2/3 pivotal study (LUTEON) | Not monetised | 2–4 years |
| Therapy (Mid-term) | TLX101-Tx | Radiopharmaceutical capable of crossing blood-brain barrier | Glioblastoma | Pivotal study enrolling | Not monetised | 2–4 years |
| Therapy (Long-term) | TLX592-Tx (²²⁵Ac Alpha-Emitter) | Next-generation alpha therapy aiming to improve efficacy and reduce off-target toxicity | Prostate cancer | Phase 1 (Alpha-PRO approved) | Not monetised | 3–5+ years |
| Therapy (Long-term) | Other Alpha & Solid Tumour Programs | Expansion into additional tumour targets using alpha emitters | Multiple cancers | Pre-clinical / early Phase 1 | Not monetised | 5+ years |
Competitive Advantage
Telix’s core competitive advantage lies in its integrated theranostic model, where diagnostics and therapeutics are developed, manufactured, and commercialised within the same ecosystem. This creates a structural edge that is difficult for single-product biotech or imaging-only competitors to replicate.
First, Telix already controls a commercially proven PSMA imaging franchise through Illuccix and Gozellix, both reimbursed and widely adopted. This provides real-world clinical data, established hospital relationships, and recurring revenue, giving Telix a head start in guiding patient selection for future therapies. Most competitors are still trying to commercialise a first product; Telix is already scaling.
Second, the company benefits from a platform-level moat. The AlFluor™ radiolabelling technology and vertically integrated manufacturing network provide supply chain control, isotope flexibility, and scalability. In radiopharmaceuticals, where logistics, shelf life, and isotope availability are critical constraints, this is a meaningful and often underestimated advantage.
Third, Telix’s innovation strategy is incremental and de-risked, not binary. Growth is driven by expanding usage of existing products (earlier diagnosis via BiPASS, broader labels, geographic expansion) rather than relying solely on single high-risk drug approvals. This reduces downside risk while preserving upside optionality.
Finally, Telix operates in clinically entrenched markets with strong guideline support. PSMA-PET imaging is now standard of care in prostate cancer, creating high barriers to displacement and long product life cycles once embedded in clinical workflows.
Technical Analysis (Using BGS 20 Metrics)
Telix is currently trading around 64% below its 2025 highs, having previously reached levels of approximately $32 (AUD). The stock has undergone a full sentiment and valuation reset, with price now well below long-term moving averages despite continued business execution. This magnitude of drawdown suggests the market has already priced in a large amount of risk, creating a technically discounted setup relative to the company’s underlying fundamentals.
✅ Price briefly broke above the short-term consolidation range around $11.20–$11.30. The breakout to the downside, failed immediately, with price closing back inside the range, which indicates it wasn’t a true breakout but liquidity grab.
✅ Strong bullish rejection candle immediately followed
→ Buyers stepped in aggressively after the failed move.
→ Indicates absorption of supply, not distribution.
✅ Higher low preserved
→ Price held above key support (~$11.20).
→ Structure did not break down.
✅ Volume confirmation
→ Green candle printed on elevated volume, suggesting real demand, not a dead-cat bounce.
Why We Like Not only Trading but also Investing in Telix
We like Telix because it combines quality fundamentals with a temporary technical dislocation. At the business level, Telix has transitioned from development to profitable commercial execution, with FY24 confirming a clear profit inflection and FY25 delivering strong revenue growth at scale. Unlike many healthcare growth stocks, Telix is no longer dependent on capital markets to fund operations.
At the strategic level, the company offers layered upside:
- Near-term cash flow from diagnostics
- Medium-term re-rating potential from Phase 3 therapeutics
- Long-term optionality from alpha-emitter programs
At the stock level, despite these strengths, Telix is trading well below long-term moving averages, reflecting sentiment and rotation rather than deterioration in fundamentals. This disconnect between price and business quality is exactly what we look for under the BGS 20 framework.
Telix represents a high-quality healthcare compounder trading at a discounted technical level, with strong competitive positioning, visible revenue, and multiple execution-driven growth levers, a combination we rarely get at this stage of maturity.
Should I Buy (ASX: TLX | NASDAQ: TLX) Now?
(Area Restricted For VIP Members Only; If You Want To Access, You Will Need To Login)
ENTRY DETAILS, TRADING CONSIDERATIONS, TARGETS, CAPITAL FLOW ANALYSTS, SHAREHOLDER STATISTICS AND HOLDING TREND
:
:
The information provided by BG Trading to you does not constitute personal financial product advice. The information provided is of a general nature only and does not take into account your individual objectives, financial situation or needs. It should not be used, relied upon, or treated as a substitute for specific professional advice. BG trading recommends that you obtain your own independent professional advice before making any decision in relation to your particular requirements or circumstances. Past performance of any product discussed is not indicative of future performance. (We urge that caution should be exercised in assessing past performance. All financial products are subject to market forces and unpredictable events that may adversely affect their future performance).